News
RGLS
2.880
0.00%
0.000
Buy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment Needs
Analyst Whitney Ijem of Canaccord Genuity has maintained a Buy rating on Regulus (RGLS) The company is developing a drug candidate for the treatment of kidney disease ADPKD. The drug candidate, RGLS8429, targets the miR-17 pathway implicated in the disease.
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Axsome Therapeutics (AXSM) and Olink Holding (OLK)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Hims & Hers Health (HIMS) and Olink Holding (OLK)
TipRanks · 1d ago
Buy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestones
TipRanks · 3d ago
Regulus Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
Weekly Report: what happened at RGLS last week (0318-0322)?
Weekly Report · 3d ago
Maintaining Hold on Regulus: A Balanced View of Financial Stability and Awaited Clinical Milestones
TipRanks · 6d ago
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023
Regulus Therapeutics reported earnings per share of -40 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -39 cents. Regulus TherAPEutics reported results for the last quarter of 2013.
Investorplace · 6d ago
Regulus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Regulus Therapeutics Inc reports results for the quarter ended in December. Reported revenue was zero; analysts expected zero. The company reported a quarterly loss of $8.06 million. Shares had risen by 95.3% this quarter. Wall Street's median 12-month price target for the company is $6.
Reuters · 03/21 21:28
Regulus Therapeutics GAAP EPS of -$0.40 in-line
Seeking Alpha · 03/21 20:46
*Regulus Therapeutics 4Q R&D Expenses $5.8M >RGLS
Dow Jones · 03/21 20:13
*Regulus Therapeutics: Oversubscribed $100M Private Placement to Extend Cash Runway Into 1H of 2026 >RGLS
Dow Jones · 03/21 20:13
Press Release: Regulus Therapeutics Reports -2-
Statements in this presentation are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ from those expressed or implied by such statements. The Company's RGLS8429 program is designed to address the underlying genetic causes of ADPKD. Regulus Therapeutics Inc. Is a biotechnology company.
Dow Jones · 03/21 20:05
*Regulus Therapeutics 4Q Loss $8.06M >RGLS
Dow Jones · 03/21 20:05
*Regulus Therapeutics 4Q Loss/Shr 40c >RGLS
Dow Jones · 03/21 20:05
Regulus Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 03/19 12:22
Regulus Therapeutics Price Target Cut to $11.00/Share From $12.00 by Canaccord Genuity
Dow Jones · 03/19 12:22
Canaccord Genuity Maintains Buy on Regulus Therapeutics, Lowers Price Target to $11
Benzinga · 03/19 12:12
U.S. RESEARCH ROUNDUP-American Tower, Lennar, Nike
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. American Tower, Lennar and Nike among companies with revised targets on Tuesday. Analysts cut target prices for American Tower and Lennar, raise targets for others. Zoom Video Communications, Darden Restaurants and others also see analyst downgrades.
Reuters · 03/19 07:17
Regulus Therapeutics Price Target Announced at $6.00/Share by Leerink Partners
Dow Jones · 03/18 12:35
More
Webull provides a variety of real-time RGLS stock news. You can receive the latest news about Regulus Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About RGLS
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.